ORMP: Gabay Avraham discloses a sale

By AlphaYouPublished Oct 2, 2026Form 4

Stocks in this disclosure

Reported activity

Gabay Avraham

Reporting filer

Gabay Avraham reported Sale in ORAMED PHARMACEUTICALS INC.: 20000 units of Common Stock, dated 2026-10-01. The full Form 4 contains 1 transaction entry.

Disclosed: Oct 2, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Common Stock	Gabay Avraham	2026-10-01	S	Sale	20000	4.510	861,076	1 day	Filed terms security Title: Common Stock transaction Date: 2026-10-01 deemed Execution Date: transaction Form Type: 4 transaction Code: S equity Swap Involved: 0 transaction Timeliness: transaction Shares: 20000 id: F1 transaction Price Per Share: 4.510 id: F2 transaction Acquired Disposed Code: D shares Owned Following Transaction: 861076 direct Or Indirect Ownership: D

Common Stock

Owner: Gabay Avraham
Date: 2026-10-01
Code: S
Action: Sale
Quantity: 20000
Price: 4.510
Following holdings: 861,076
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Common Stock
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: S
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 20000
id: F1
transaction Price Per Share: 4.510
id: F2
transaction Acquired Disposed Code: D
shares Owned Following Transaction: 861076
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Gabay Avraham: Chief Financial Officer.
The filing reports a Rule 10b5-1 trading plan.
F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Common Stock

Gabay Avraham

2026-10-01

Sale

20000

4.510

861,076

1 day

Filed terms

security Title: Common Stock
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: S
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 20000
id: F1
transaction Price Per Share: 4.510
id: F2
transaction Acquired Disposed Code: D
shares Owned Following Transaction: 861076
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Gabay Avraham: Chief Financial Officer.

The filing reports a Rule 10b5-1 trading plan.

F1: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.